A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease

New York Presbyterian Hospital, New York

Daniel Present, New York

Long Island Clinical Research Associates, Great Neck

NY Center for Clinical Research, Lake Success

Rochester Institute for Digestive Diseases, Rochester

Peter Molloy, MD, Pittsburgh

Altoona Center for Clinical Research, Duncansville

Digestive Disorders Associates, Annapolis

Charlottesville Medical Research, Charlottesville

Digestive Health Specialists, Winston-Salem

UNC School of Medicine, Chapel Hill

Wake Research Associates, Raleigh

Charlotte Gastroenterology and Hepatology, Charlotte

Carolina Research Associates, Charlotte

Atlanta Gastroenterology Assoc., Atlanta

Southeastern Digestive & Liver Disease, Savannah

Shafran Gastroenterology Center, Winter Park

Cleveland Clinic Florida, Weston

Nashville Medical Research Institute, Nashville

Diseases of the Digestive System, Chattanooga

Consultants for Clinical Research, Cincinnati

Wisconsin Center for Advanced Research, Milwaukee

Mayo Clinic and Mayo Foundation, Rochester

Deaconess Billings Clinic Research Division, Billings

University of Chicago, Chicago

Gastroenterology and Hepatology, Kansas City

Glenn Gordon, MD, Mexico

Gastroenterology Specialties, P.C., Lincoln

Drug Research Services, Inc., Metairie

LSU School of Medicine, New Orleans

Oklahoma Foundation for Digestive Disease, Oklahoma City

Research Solutions, Tulsa

Long Beach Gastroenterology Assoc., Long Beach

Sharp Rees-Stealy Medical Group, San Diego

Gastroenterology Associates of the East Bay, Berkeley

Northwest Gastroenterology, Bellevue

Tacoma Digestive Disease Center, Tacoma

Inland Empire Gastroenterology, Spokane

Northwest Gastroenterologists, S.C., Arlington Heights

Gastroenterology Assoc. of Fairfield Co., Bridgeport

Brigham and Women's Hospital, Boston

Massachusetts General Hospital, Boston

Clinical Pharmacology Study Group, Worcester